{"id":625,"date":"2020-11-05T05:59:21","date_gmt":"2020-11-05T05:59:21","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=625"},"modified":"2020-11-30T12:00:37","modified_gmt":"2020-11-30T12:00:37","slug":"01-nov-2020-favipiravir-lopinavir-r-fpv-found-to-more-beneficial-in-icu-patients-compared-to-lpv-r","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/01-nov-2020-favipiravir-lopinavir-r-fpv-found-to-more-beneficial-in-icu-patients-compared-to-lpv-r\/","title":{"rendered":"(01 Nov 2020) Favipiravir, Lopinavir\/R- FPV found to be more beneficial in ICU patients compared to LPV\/r"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Observational study of the effects of Favipiravir vs Lopinavir\/Ritonavir on clinical outcomes in critically Ill patients with COVID-19<\/p>\n<p>https:\/\/doi.org\/10.1111\/jcpt.13305<\/p>\n<p class=\"\">The aim of this study was to describe the clinical experience with FPV and LPV\/r in critically ill patients with COVID-19 at Sakarya University Education and Research Hospital. The study included 107 consecutive patients who had a laboratory confirmation of COVID-19 and were admitted to the intensive care unit (ICU) .&nbsp; Of the 107 patients, 65 received FPV (Group FPV) and 42 received LPV\/r (Group LPV\/r). The two groups were similar in terms of demographic data and clinical findings. 43 (66.2%) of the 65 patients in the FPV group and 23 (54.8%) of the 42 patients in the LPV\/r group died (p = 0.237). The median ICU stay was 6.6 (IQR, 3-10) days in the FPV group and 9 (IQR, 6-16) days in the LPV\/r group, which was a statistically significant difference (p = 0.010).&nbsp; The length of hospital stay was significantly lower in the FVP group compared to the LPV\/r group among patients who were discharged from the ICU. Although the analysis was done with a limited number of patients and the observed difference in mortality rate is of some concern, FVP treatment may be more beneficial than LPV\/r in terms of effective use in the ICU.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Observational study of the effects of Favipiravir vs Lopinavir\/Ritonavir on clinical outcomes in critically Ill patients with COVID-19 https:\/\/doi.org\/10.1111\/jcpt.13305 The aim of this study was to describe the clinical experience with FPV and LPV\/r in critically ill patients with COVID-19&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/01-nov-2020-favipiravir-lopinavir-r-fpv-found-to-more-beneficial-in-icu-patients-compared-to-lpv-r\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(01 Nov 2020) Favipiravir, Lopinavir\/R- FPV found to be more beneficial in ICU patients compared to LPV\/r&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,11,12],"tags":[26,41],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/625"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=625"}],"version-history":[{"count":2,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/625\/revisions"}],"predecessor-version":[{"id":686,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/625\/revisions\/686"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}